Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Ayvakit® (avapritinib) – New orphan indication
May 22, 2023 - Blueprint Medicines announced the FDA approval of Ayvakit (avapritinib), for the treatment of adult patients with indolent systemic mastocytosis (ISM).
